Evidence map›Paper›PMID 40421185›Full record

ArticleRespirology case reports2025

Recurrent Drug-Induced Pneumothorax Associated With Lenvatinib: A Case Report.

Ryo Torii, Kei Yamasaki, Yutaka Ishiguro, Tatsuya Shingu, Ryosuke Hata, Kazuhiro Yatera

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respirology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ryo ToriiDepartment of Respiratory Medicine Wakamatsu Hospital of the University of Occupational and Environmental Health, Japan Kitakyushu Japan.
Kei YamasakiDepartment of Respiratory Medicine Wakamatsu Hospital of the University of Occupational and Environmental Health, Japan Kitakyushu Japan.ORCID https://orcid.org/0000-0003-1876-3287
Yutaka IshiguroDepartment of Respiratory Medicine Wakamatsu Hospital of the University of Occupational and Environmental Health, Japan Kitakyushu Japan.
Tatsuya ShinguDepartment of Respiratory Medicine Wakamatsu Hospital of the University of Occupational and Environmental Health, Japan Kitakyushu Japan.
Ryosuke HataDepartment of Respiratory Medicine Wakamatsu Hospital of the University of Occupational and Environmental Health, Japan Kitakyushu Japan.
Kazuhiro YateraDepartment of Respiratory Medicine University of Occupational and Environmental Health, Japan Kitakyushu Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a patient with recurrent pneumothorax induced by lenvatinib, used for the treatment of thymic carcinoma. A 76-year-old Japanese man, who is a current smoker, was diagnosed with thymic carcinoma with pulmonary metastasis and pleural dissemination. Lenvatinib was initiated as third-line chemotherapy in April 2022. He was subsequently admitted to our hospital in August and October 2023 for recurrent left-sided pneumothorax. Following the second left pneumothorax, lenvatinib was discontinued, and he has remained free of pneumothorax for over a year. Clinicians should be aware of the potential adverse effects of lenvatinib in patients with pulmonary metastasis or pleural dissemination.

Indexed as

lenvatinibpleural disseminationpneumothoraxpulmonary metastasisthymic carcinoma

Identifiers

PMID40421185
PMCPMC12105871

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.